TY - JOUR
T1 - Screening for Barrett's esophagus
AU - Di Pietro, Massimiliano
AU - Chan, Daniel
AU - Fitzgerald, Rebecca C.
AU - Wang, Kenneth K.
N1 - Funding Information:
Funding Supported by core funding from the Medical Research Council (to R.C.F.) and National Cancer Institute grants U01 CA182940 , U54 CA163004 , and U54 CA163059 (to K.K.W.).
Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - The large increase in the incidence of esophageal adenocarcinoma in the West during the past 30 years has stimulated interest in screening for Barrett's esophagus (BE), a precursor to esophageal cancer. Effective endoscopic treatments for dysplasia and intramucosal cancer, coupled with screening programs to detect BE, could help reverse the increase in the incidence of esophageal cancer. However, there are no accurate, cost-effective, minimally invasive techniques available to screen for BE, reducing the enthusiasm of gastroenterologists. Over the past 5 years, there has been significant progress in the development of screening technologies. We review existing and developing technologies, new minimally invasive imaging techniques, nonendoscopic devices for cell collection, and biomarkers that can be measured in blood or stool samples. We discuss the status of these approaches, data from clinical studies of their effects, and their anticipated strengths and weaknesses in screening. The area is rapidly evolving, and new tools will soon be ready for prime time.
AB - The large increase in the incidence of esophageal adenocarcinoma in the West during the past 30 years has stimulated interest in screening for Barrett's esophagus (BE), a precursor to esophageal cancer. Effective endoscopic treatments for dysplasia and intramucosal cancer, coupled with screening programs to detect BE, could help reverse the increase in the incidence of esophageal cancer. However, there are no accurate, cost-effective, minimally invasive techniques available to screen for BE, reducing the enthusiasm of gastroenterologists. Over the past 5 years, there has been significant progress in the development of screening technologies. We review existing and developing technologies, new minimally invasive imaging techniques, nonendoscopic devices for cell collection, and biomarkers that can be measured in blood or stool samples. We discuss the status of these approaches, data from clinical studies of their effects, and their anticipated strengths and weaknesses in screening. The area is rapidly evolving, and new tools will soon be ready for prime time.
KW - Biomarkers
KW - Biophotonics
KW - Cytology
KW - Endoscopy
KW - FISH
UR - http://www.scopus.com/inward/record.url?scp=84928597147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928597147&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2015.02.012
DO - 10.1053/j.gastro.2015.02.012
M3 - Review article
C2 - 25701083
AN - SCOPUS:84928597147
SN - 0016-5085
VL - 148
SP - 912
EP - 923
JO - Gastroenterology
JF - Gastroenterology
IS - 5
ER -